Theme image. — © BELGA
The French biotech company AbolerIS Pharma moved from Nantes in France to Gosselies near Charleroi. De Tijd, L’Echo and SudInfo reported this on Tuesday. The company added 27.3 million euros, says Flemish CEO Ann Meulemans.
Today at 05:49
The company was founded in 2019 by researchers from the University of Nantes. It develops candidate treatments for inflammatory diseases and chronic autoimmune conditions. The company wants to start the first clinical study with its most advanced drug, against rheumatoid arthritis, in mid-2024.
The Belgian biotech fund Newton Biocapital was one of the leaders of the capital round, together with the Spanish Caixa Capital Risc and Sound Bioventures from Scandinavia. A number of Belgian and Walloon government funds also invested. “We therefore thought it would be fair to establish ourselves in Wallonia,” says Meulemans, who became CEO of AbolerIS at the end of 2020, in De Tijd. “In addition, we have space available that we did not have in Nantes.”